David Dennis, MD
Pulmonary Disease · Charleston, SCNPI 1740711811
Payments from drug & device makers
Across 108 payments — averaging $53.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Sanofi$512
- Regeneron Healthcare Solutions, Inc.$417
- United Therapeutics Corporation$296
- AstraZeneca$222
- GSK$183
- plus $631 from 13 others
What the payments were for
- Travel & lodging$93716%
- Food & beverage$2,16137%
- Education$2,66846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,505 |
| Sanofi | 30 | $512 |
| Regeneron Healthcare Solutions, Inc. | 12 | $417 |
| United Therapeutics Corporation | 5 | $296 |
| AstraZeneca | 11 | $222 |
| GSK | 14 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $123 |
| Inspire Medical Systems, Inc. | 5 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Insmed, Inc. | 3 | $55 |
| Amgen | 3 | $50 |
| Verona Pharma, Inc. | 2 | $46 |
| Viatris Specialty LLC | 2 | $39 |
| Fisher & Paykel Healthcare Inc | 1 | $29 |
| Pulmonx Corporation | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,407
- DUPIXENT$121
How this compares
$5,766 in reported general payments places this provider in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 290 | $216,878 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 248 | $177,778 |
| Dupixent PenDupilumab | 11 | $42,473 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $29,476 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $22,481 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $15,363 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $9,935 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,896 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $9,309 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 61 | $8,502 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 283 | $5,737 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,691 |
| Roflumilast | 38 | $3,508 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $2,420 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $2,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $183 | $254,721364 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $222 | $187,087286 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $14 | $49,30685 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Charleston
- Patrick FlumeCharleston$4.6M
- Barry SigalCharleston$1.4M
- Gerard SilvestriCharleston$1.2M
- Rachana KrishnaCharleston$1M
- John HugginsCharleston$885K
- Timothy WhelanCharleston$885K
- Walter JamesCharleston$109K
- John CoxCharleston$95K
- Denise Gabrielle SeseCharleston$75K
- Lauren SullivanCharleston$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.